|
Description:
|
|
The industry is at a unique crossroads: pharmaceutical and digital therapeutic (DTx) companies have begun to act on their ambition to advance digital therapeutics—but the path to successful alliances and, importantly, scale remains uncertain. As a follow up to our recent research on building pharma-DTx alliances, we sat down with two leaders to get their perspective on:
-The dos and don'ts of pharma-DTx partnerships
-Evidence standards for digital therapeutics
-Channel pathways and business models for DTx companies
-Assessing the value of working with pharma as a DTx company
Hear from ZS' Paul Darling, Novo Nordisk's Amy West, Pear Therapeutics' Corey McCann, and Rock Health's Megan Zweig in our latest podcast episode. |
.png)
More
Religion & Spirituality
Education
Arts and Design
Health
Fashion & Beauty
Government & Organizations
Kids & family
Music
News & Politics
Science & Medicine
Society & Culture
Sports & Recreation
TV & Film
Technology
Philosophy
Storytelling
Horror and Paranomal
True Crime
Leisure
Travel
Fiction
Crypto
Marketing
History
Comedy
Arts
Games & Hobbies
Business
Motivation